Stakes could not be higher for Vivoryon ahead of Alzheimer's readout

Germany-based Vivoryon Therapeutics  (Euronext: VVY) could well be on the path towards altering the course of Alzheimer’s disease (AD), with a PhII data readout coming up and an option offering potential advantages over recently-approved monoclonal antibodies (MAbs).

The company's approach is applying its expertise in understanding post-translational modifications to develop therapeutics that modulate the activity and stability of proteins altered in disease settings.

In AD, Vivoryon is tackling all major hallmarks of the disease with an innovative approach of targeting glutaminyl-peptide cyclotransferase-like (QPCT/L), the enzyme responsible for the toxic amyloid species N3pE, an important driver of the AD pathology.